Cemacabtagene ansegedleucel

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameCemacabtagene ansegedleucel

Drug Alias Namecema-cel (Allogene Therapeutics)next-generation anti-CD19 AlloCAR T (Allogene Therapeutics)ALLO-501AALLO-501.1

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumCanadaUnited States +[4]

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesCellectis Sa

China Registration ClassN/A

Develop Information

Active CompaniesAllogene Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A